Division of Infection, Barts & The London NHS Trust, London, UK.
Int J Antimicrob Agents. 2010 Mar;35(3):219-26. doi: 10.1016/j.ijantimicag.2009.10.024. Epub 2010 Jan 4.
Infection due to Acinetobacter baumannii has become a significant challenge to modern healthcare systems. The organism shows a formidable capacity to develop antimicrobial resistance, yet the clinical impact of A. baumannii infection remains unclear. Much is known about the processes involved in multidrug resistance, but those underlying the pathogenicity and virulence potential of the organism are only beginning to be elucidated. In this article, we provide an overview of current knowledge, focusing on mechanisms of pathogenesis, the molecular basis of resistance and options for treatment in the absence of novel therapeutic agents.
鲍曼不动杆菌感染已成为现代医疗体系的重大挑战。该菌对抗菌药物的耐药性形成能力极强,但鲍曼不动杆菌感染的临床影响仍不明确。人们对其多重耐药机制已有较多了解,但对其致病性和毒力潜能的相关机制仍知之甚少。本文就目前的相关知识进行综述,重点关注发病机制、耐药的分子基础,以及在尚无新型治疗药物的情况下的治疗选择。